Biopharmconsortium Blog

Expert commentary from Haberman Associates biotechnology and pharmaceutical consulting.

Posts filed under: Infectious disease

Chemokine receptors and the HIV-1 entry inhibitor maraviroc

TweetIn April 2012, Informa’s Scrip Insights published our book-length report, “Advances in the Discovery of Protein-Protein Interaction Modulators.” We also published a brief introduction to this report, highlighting the strategic importance of protein-protein interaction (PPI) modulators for the pharmaceutical industry, on the Biopharmconsortium Blog. The report included a discussion on discovery and development of inhibitors…

Haberman Associates in “Pink Sheet” article on the cystic fibrosis drug market

Tweet  I was quoted in an article in the March 11, 2013 issue of Elsevier Business Intelligence’s The Pink Sheet by senior writer Joseph Haas. The article is entitled “Cystic Fibrosis Market Snapshot: Disease-Modifying Drugs Elusive 24 Years After Discovery Of Root Cause”. A subscription is required to view the full text of this article….

Developing resistance-free antibiotics by targeting quorum sensing

Tweet  Way back in May 2000, Decision Resources published my short report entitled “New approaches to small-molecule antibacterial drug discovery” as part of its Spectrum Life Sciences series. As might be expected, the report is now out of print. The report was a brief review of then-novel approaches to antibacterial drug discovery, in the face…

The 2011 Nobel Prize in Physiology or Medicine–Innate and Adaptive Immunity

Tweet  Our November 25, 2011 article on this blog focused on Ralph Steinman, one of the three winners of The Nobel Prize in Physiology or Medicine for 2011. That article focused on dendritic cell-based vaccines for cancer, and the application of this area of science and technology to treating Dr. Steinman’s own pancreatic cancer. Dr….

ZymoGenetics CEO Doug Williams moves to Biogen Idec as R&D chief

TweetIn our November 11, 2010 blog post, we discussed the September 2010 acquisition of Seattle biotech firm ZymoGenetics by Bristol-Myers Squibb (BMS). Also in November 2010, Nature Biotechnology published an article about this acquisition, in which I was quoted. As our blog post states, most commentators believe that BMS’ main motivation for acquiring ZymoGenetics was…

Haberman Associates in Nature Biotechnology article on Bristol-Myers Squibb acquisition of ZymoGenetics

TweetI was quoted in an article entitled “Bristol-Myers Squibb reaps biologics in ZymoGenetics windfall”, by freelance journalist Emma Dorey (Brighton, UK), in the November 2010 issue of Nature Biotechnology. The article focused on the acquisition of ZymoGenetics (Seattle, WA) by Bristol-Myers Squibb (BMS). To read the article, go to the Nature Biotechnology website. Interestingly, I…